Ballentine Partners, LLC 10x Genomics, Inc. Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in 10x Genomics, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 15,688 shares of TXG stock, worth $249,282. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,688
Previous 15,574
0.73%
Holding current value
$249,282
Previous $180,000
1.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TXG
# of Institutions
353Shares Held
118MCall Options Held
266KPut Options Held
191K-
Vanguard Group Inc Valley Forge, PA13.3MShares$211 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.9MShares$189 Million0.98% of portfolio
-
Black Rock Inc. New York, NY6.39MShares$102 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.44MShares$86.4 Million0.03% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.5.38MShares$85.5 Million0.04% of portfolio
About 10x Genomics, Inc.
- Ticker TXG
- Exchange NASDAQ
- Sector Healthcare
- Industry Health Information Services
- Shares Outstandng 95,046,400
- Market Cap $1.51B
- Description
- 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumabl...